Brainstorm Cell Therapeutics develops autologous cellular therapies to treat neurodegenerative diseases. The company uses its NurOwn platform to induce stem cells to secrete neurotrophic factors and modulate disease processes. NurOwn has completed Phase III trials for ALS treatment and is also being developed for MS, Alzheimers, and other neurodegenerative diseases.
| Indicator | Value |
|---|---|
| PER | 56.1 |
| EV/EBITDA | 31.6 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 18.4% |
| Net Debt/EBITDA | 3.3 |